How much does EDARBI (Azilsartan Medoxomil Potassium Tablets) Cost& price without insurance in China?
EDARBI® is the commercial brand name of Azilsartan Medoxomil Potassium Tablets, developed by Takeda Pharma A/S. It is an oral angiotensin II type 1 receptor antagonist. It selectively blocks angiotensin II receptors on vascular smooth muscle to dilate blood vessels, reduce peripheral vascular resistance and lower blood pressure with long-lasting antihypertensive effects over 24 hours.
Main Indications
Treatment of essential hypertension in adult patients.
Clinical Research
Global multicenter pivotal trials fully validated its stable long-term antihypertensive efficacy for hypertensive populations;
Phase III registration trials confirmed superior 24-hour smooth blood pressure control compared with other oral ARB agents;
Combination therapy observational studies demonstrated synergistic hypotensive effect when combined with thiazide diuretics;
Dose titration comparative research identified optimal single daily dosing with balanced efficacy and tolerability;
Long-term follow-up trials verified sustained cardiovascular protective benefits and controllable overall adverse reaction spectrum.
Common Side Effects
Common mild adverse reactions: Dizziness, fatigue, diarrhea, nausea and orthostatic hypotension;
Laboratory abnormalities: Rare transient mild elevation of serum creatinine and hyperkalemia;
Severe but uncommon risks: Severe hypotension, renal function deterioration, angioedema and hypersensitivity reactions.
Approval Status in China
EDARBI® (specification 80mg per tablet, 7 tablets × 2 blisters per box) obtained marketing approval in China in 2014. It is an oral prescription antihypertensive drug included in China’s Category B medical insurance catalogue.
Buy EDARBI (Azilsartan Medoxomil Potassium Tablets) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
